Key facts
- Nervonik’s last known valuation is $44.0M (Feb 2025).
- It has raised $17.5M; the latest was Later Stage VC ($13.0M) in Feb 2025.
- Notable investors include University of California, Correlation Ventures, Joyance Partners, Foothill Ventures, Camford Capital — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Nervonik
- ·The full record, as it builds
Funding rounds
No funding rounds for Nervonik are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nervonik
Developer of a neuro-modulation device for therapeutic applications. The company's device specializes in novel miniaturized sensing feedback to provide closed-loop optimized therapy, enabling patients to get the required treatment for chronic neuropathic pain.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2020
- Employees
- 11
- Website
- nervonik.com/
- Ownership
- Privately Held (backing)
Nervonik doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nervonik shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nervonik in its N-PORT filings yet. We sweep new filings monthly.